Kedrion

Company snapshot

At Kedrion, we believe that innovation and care must go hand in hand. Our mission is to enhance lives through our dedicated work in the field of rare and ultra-rare diseases. As a global leader with a passionate team of 5,200 employees, we collect and fractionate plasma to produce and distribute 38 vital medicines worldwide, establishing ourselves as the fifth largest player in the plasma-derived

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Kedrion. Not investment advice.

• What is Kedrion?

  Kedrion S.p.A is a pharma organization headquartered in BARGA, IT. Primary therapeutic focus areas include Chronic Immune Thrombocytopenia (ITP). NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTri

• Is Kedrion publicly traded?

  Kedrion appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Kedrion develop or market?

  No drug profiles are currently linked to Kedrion. Pipeline programs may still list investigational assets.

• What are the latest developments for Kedrion?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Kedrion focus on?

  Kedrion focuses on Chronic Immune Thrombocytopenia (ITP) based on our analysis of their pipeline programs and drug development activities.